Drug intelligence / Profile preview

GV-HPAI

Development stage: Preclinical
Lead developer: GreenVax
Modality: Vaccines & Immunotherapeutics

Overview

GV-HPAI (also known as GEV-006) is a live-attenuated vaccine candidate being developed by GreenVax for the prevention of highly pathogenic avian influenza (HPAI). The vaccine is designed to protect against avian influenza viruses, which primarily affect poultry such as chickens and ducks but pose a high mortality risk if transmitted to humans. GV-HPAI is currently in the basic research stage of development.

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on GV-HPAI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GV-HPAI.